We then highlight emerging therapeutic strategies targeting this biomarker, followed by an in-depth discussion of novel applications and limitations of CLDN18.2-targeted theranostics in various cancers represented by digestive system tumors. Here, CLDN18 is linked to digestive system neoplasm.